RDY
Price
$14.22
Change
+$0.06 (+0.42%)
Updated
Sep 26 closing price
Capitalization
11.75B
27 days until earnings call
TAK
Price
$14.74
Change
+$0.09 (+0.61%)
Updated
Sep 26 closing price
Capitalization
47.11B
33 days until earnings call
Interact to see
Advertisement

RDY vs TAK

Header iconRDY vs TAK Comparison
Open Charts RDY vs TAKBanner chart's image
Dr. Reddy's Laboratories
Price$14.22
Change+$0.06 (+0.42%)
Volume$1.21M
Capitalization11.75B
Takeda Pharmaceutical
Price$14.74
Change+$0.09 (+0.61%)
Volume$1.47M
Capitalization47.11B
RDY vs TAK Comparison Chart in %
Loading...
RDY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
TAK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
RDY vs. TAK commentary
Sep 28, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is RDY is a Buy and TAK is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 28, 2025
Stock price -- (RDY: $14.22 vs. TAK: $14.74)
Brand notoriety: RDY and TAK are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: RDY: 112% vs. TAK: 39%
Market capitalization -- RDY: $11.75B vs. TAK: $47.11B
RDY [@Pharmaceuticals: Generic] is valued at $11.75B. TAK’s [@Pharmaceuticals: Generic] market capitalization is $47.11B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $63.66B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.83B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

RDY’s FA Score shows that 0 FA rating(s) are green whileTAK’s FA Score has 2 green FA rating(s).

  • RDY’s FA Score: 0 green, 5 red.
  • TAK’s FA Score: 2 green, 3 red.
According to our system of comparison, TAK is a better buy in the long-term than RDY.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

RDY’s TA Score shows that 5 TA indicator(s) are bullish while TAK’s TA Score has 5 bullish TA indicator(s).

  • RDY’s TA Score: 5 bullish, 5 bearish.
  • TAK’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, both RDY and TAK are a bad buy in the short-term.

Price Growth

RDY (@Pharmaceuticals: Generic) experienced а -4.37% price change this week, while TAK (@Pharmaceuticals: Generic) price change was -2.12% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -1.16%. For the same industry, the average monthly price growth was +24.25%, and the average quarterly price growth was +66.99%.

Reported Earning Dates

RDY is expected to report earnings on Oct 24, 2025.

TAK is expected to report earnings on Oct 30, 2025.

Industries' Descriptions

@Pharmaceuticals: Generic (-1.16% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
TAK($47.1B) has a higher market cap than RDY($11.7B). TAK has higher P/E ratio than RDY: TAK (51.28) vs RDY (18.54). TAK YTD gains are higher at: 11.329 vs. RDY (-9.379). TAK has higher annual earnings (EBITDA): 1.13T vs. RDY (98.1B). TAK has more cash in the bank: 419B vs. RDY (66.7B). RDY has less debt than TAK: RDY (48.6B) vs TAK (4.51T). TAK has higher revenues than RDY: TAK (4.48T) vs RDY (334B).
RDYTAKRDY / TAK
Capitalization11.7B47.1B25%
EBITDA98.1B1.13T9%
Gain YTD-9.37911.329-83%
P/E Ratio18.5451.2836%
Revenue334B4.48T7%
Total Cash66.7B419B16%
Total Debt48.6B4.51T1%
FUNDAMENTALS RATINGS
RDY vs TAK: Fundamental Ratings
RDY
TAK
OUTLOOK RATING
1..100
6463
VALUATION
overvalued / fair valued / undervalued
1..100
77
Overvalued
5
Undervalued
PROFIT vs RISK RATING
1..100
50100
SMR RATING
1..100
5289
PRICE GROWTH RATING
1..100
5960
P/E GROWTH RATING
1..100
5432
SEASONALITY SCORE
1..100
5085

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TAK's Valuation (5) in the Pharmaceuticals Major industry is significantly better than the same rating for RDY (77) in the Pharmaceuticals Generic industry. This means that TAK’s stock grew significantly faster than RDY’s over the last 12 months.

RDY's Profit vs Risk Rating (50) in the Pharmaceuticals Generic industry is somewhat better than the same rating for TAK (100) in the Pharmaceuticals Major industry. This means that RDY’s stock grew somewhat faster than TAK’s over the last 12 months.

RDY's SMR Rating (52) in the Pharmaceuticals Generic industry is somewhat better than the same rating for TAK (89) in the Pharmaceuticals Major industry. This means that RDY’s stock grew somewhat faster than TAK’s over the last 12 months.

RDY's Price Growth Rating (59) in the Pharmaceuticals Generic industry is in the same range as TAK (60) in the Pharmaceuticals Major industry. This means that RDY’s stock grew similarly to TAK’s over the last 12 months.

TAK's P/E Growth Rating (32) in the Pharmaceuticals Major industry is in the same range as RDY (54) in the Pharmaceuticals Generic industry. This means that TAK’s stock grew similarly to RDY’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
RDYTAK
RSI
ODDS (%)
Bearish Trend 3 days ago
64%
Bearish Trend 4 days ago
68%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
50%
Bullish Trend 3 days ago
43%
Momentum
ODDS (%)
Bearish Trend 3 days ago
53%
Bearish Trend 3 days ago
52%
MACD
ODDS (%)
Bearish Trend 3 days ago
59%
Bearish Trend 3 days ago
43%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
53%
Bearish Trend 3 days ago
49%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
45%
Bearish Trend 3 days ago
40%
Advances
ODDS (%)
Bullish Trend 12 days ago
49%
Bullish Trend 18 days ago
43%
Declines
ODDS (%)
Bearish Trend 4 days ago
54%
Bearish Trend 4 days ago
45%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
58%
Bullish Trend 3 days ago
61%
Aroon
ODDS (%)
Bullish Trend 3 days ago
43%
Bullish Trend 3 days ago
37%
View a ticker or compare two or three
Interact to see
Advertisement
RDY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
TAK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
EUDV51.650.41
+0.79%
ProShares MSCI Europe Dividend Gr ETF
FCOM71.300.35
+0.49%
Fidelity MSCI Communication ServicesETF
PSMR29.220.05
+0.18%
Pacer Swan SOS Moderate (April) ETF
TEKY37.66-0.33
-0.86%
Lazard Next Gen Technologies ETF
ARDC13.99-0.15
-1.06%
Ares Dynamic Credit Allocation Fund

RDY and

Correlation & Price change

A.I.dvisor tells us that RDY and COLL have been poorly correlated (+29% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that RDY and COLL's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RDY
1D Price
Change %
RDY100%
+0.42%
COLL - RDY
29%
Poorly correlated
-0.69%
HROW - RDY
28%
Poorly correlated
+2.06%
VTRS - RDY
27%
Poorly correlated
+0.32%
AVDL - RDY
27%
Poorly correlated
+0.07%
AMPH - RDY
26%
Poorly correlated
+1.86%
More

TAK and

Correlation & Price change

A.I.dvisor indicates that over the last year, TAK has been loosely correlated with HLN. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if TAK jumps, then HLN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To TAK
1D Price
Change %
TAK100%
+0.61%
HLN - TAK
43%
Loosely correlated
+1.15%
ZTS - TAK
30%
Poorly correlated
+1.68%
RDY - TAK
25%
Poorly correlated
+0.42%
EOLS - TAK
24%
Poorly correlated
+0.17%
EVO - TAK
23%
Poorly correlated
-1.69%
More